Development and strategies of cell-culture technology for influenza vaccine

Applied Microbiology and Biotechnology

Volumn 89, Issue 4, 2011, Pages 893-902

  Feng, Shao Zhen ^a   Jiao, Pei Rong ^a   Qi, Wen Bao ^a   Fan, Hui Ying ^a   Liao, Ming ^a  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Cell culture; Development; Influenza virus; Strategies; Vaccine

Indexed keywords

ANCHORAGE-DEPENDENT CELLS; CHICKEN EMBRYO; COMMON PROBLEMS; CONTAGIOUS DISEASE; CULTURE SYSTEMS; DEVELOPMENT; IN-CELL; INFLUENZA VACCINES; INFLUENZA VIRUS; STRATEGIES; VACCINE PRODUCTION;

ANCHORAGES (FOUNDATIONS); ANIMAL CELL CULTURE; PLANNING; VACCINES; VIRUSES;

CELL CULTURE;

AGGRIPAL; ANTIGEN; DNA VACCINE; FLUVIRAL; H1NI VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; NOVAVAX; OPTAFUL; PREFLUCEL; TRIPLE VACCINE; UNCLASSIFIED DRUG; VAXFECTIN; VIROSOME VACCINE; VIRUS PROTEIN;

CELL ORGANELLE; DISEASE PREVALENCE; EMBRYO; HEALTH RISK; INFLUENZA; POULTRY; STRATEGIC APPROACH; VACCINATION;

ANIMAL CELL; ANIMAL CELL CULTURE; CELL CULTURE; CELL STRAIN; FERMENTATION TECHNIQUE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; SHORT SURVEY; VACCINE PRODUCTION; VERO CELL; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; TECHNOLOGY, PHARMACEUTICAL;

ORTHOMYXOVIRIDAE;

EID: 79952532845     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-010-2973-9     Document Type: Short Survey

References (86)

1. Astley K, Naciri M, Racher A, Al-Rubeai M (2007) The role of p21cip1 in adaptation of CHO cells to suspension and proteinfree culture. J Biotechnol 130:282-290 (Pubitemid 46920542)
2. Barbosa T, Zavala G, Cheng S (2008) Molecular characterization of three recombinant isolates of avian leukosis virus obtained from contaminated Marek's disease vaccines. Avian Dis 52:245-252 (Pubitemid 351883738)
3. Barrett PN, Portsmouth D, Ehrlich HJ (2010) Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 12:21-30
4. Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ (1999) Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 98:93-100
5. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878 (Pubitemid 46589748)
6. Brown DW, Kawaoka Y, Webster RG, Robinson HL (1992) Assessment of retrovirus- expressed nucleoprotein as a vaccine against lethal influenza virus infections of chickens. Avian Dis 36:515-520
7. Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR (2006) Development and use of fowlpox vectored vaccines for avian influenza. Ann N Y Acad Sci 1081:193-201 (Pubitemid 44968773)
8. Butler M, BurgenerA PatrickM, Berry M, Moffatt D, Huzel N, Barnabé N, Coombs K (2000) Application of a serum-free media for the growth of Vero cells and the production of reovirus. Biotechnol Prog 16:854-858
9. Chen H, Bu Z (2009) Development and application of avian influenza vaccines in China. Curr Top Microbiol Immunol 333:153-162
10. Chisti Y, Moo-Young M (1994) Anchorage-dependent animal cell culture in packed beds with airlift driven liquid circulation: a theoretical analysis of oxygen transfer and comparison with stirred tank microcarrier culture system. Trans Inst Chem Eng 72C:92-94
11. Choi SK, Chang HN, Lee GM, Kim IH, Oh DJ (1995) High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system. Cytotechnology 17:173-183
12. Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J (2009) Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci U S A 106:14802-14807
13. Cox MM, Hollister JR (2009) FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37:182-189
14. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR (2009) A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27:1889-1897
15. de Bruijn IA, Nauta J, Gerez L, Palache AM (2004) Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 103:139-145 (Pubitemid 38659591)
16. De BK, Shaw MW, Rota PA, Harmon MW, Esposito JJ, Rott R, Cox NJ, Kendal AP (1988) Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus. Vaccine 6:257-261
17. Doroshenko A, Halperin SA (2009) Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 8:679-688
18. Edwards KM, Sabow A, Pasternak A, Boslego JW (2009) Strategies for broad global access to pandemic influenza vaccines. Curr Top Microbiol Immunol 333:471-493
19. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358:2573-2584
20. Falk K, Rözschke O, Deres K, Metzger J, Jung G, Rammensee HG (1991) Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 174:425-434
21. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80:1959-1964 (Pubitemid 43228735)
22. Genzel Y, Behrendt I, König S, Sann H, Reichl U (2004) Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22:2202-2008
23. Genzel Y, Ritter JB, König S, Alt R, Reichl U (2005) Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog 21:58-69 (Pubitemid 40218472)
24. Genzel Y, Fischer M, Reichl U (2006) Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 24:3261-3272
25. Glacken MW, Fleischaker RJ, Sinskey AJ (1986) Reduction of waste product excretion via nutrient control: possible strategies for maximizing product and cell yields on serum in cultures of mammalian cells. Biotechnol Bioeng 28:1376-1389 (Pubitemid 16635886)
26. Gregersen JP (2008) A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 26:3332-3340
27. Halperin SA, Smith B, Mabrouk T, Germain M, Trépanier P, Hassell T, Treanor J, Gauthier R, Mills EL (2002) Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247 (Pubitemid 34135962)
28. Hassell T, Butler M (1990) Adaptation to non-ammoniagenic medium and selective substrate feeding lead to enhanced yields in animal cell cultures. J Cell Sci 96:501-508
29. Hassell T, Gleave S, Butler M (1991) Growth inhibition in animal cell culture. The effect of lactate and ammonia. Appl Biochem Biotechnol 30:29-41
30. Hoffmann HH, Palese P, Shaw ML (2008) Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res 80:124-134
31. Hornícková Z (1997) Different progress of MDCK cell death after infection by two different influenza virus isolates. Cell Biochem Funct 15:87-93
32. Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS (2008) Microcarrierbased MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine 26:5736-5740
33. Ikić D (1969) Experience in Yugoslavia with live influenza vaccine prepared from an attenuated A2-Hong Kong-68 strain. Bull World Health Organ 41:608-609
34. Jayme DW, Blackman KE (1985) Culture media for propagation of mammalian cells, viruses, and other biologicals. Adv Biotechnol Processes 5:1-30
35. Katz J, Webster R (1992) Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol 73:1159-1165
36. Katz JM, Naeve CW, Webster RG (1987) Host cell-mediated variation in H3N2 influenza viruses. Virology 156:386-395 (Pubitemid 17021033)
37. Kaverin NV, Webster RG (1995) Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol 69:2700-2703
38. Kessler N, Thomas-Roche G, Gerentes L, Aymard M (1999) Suitability of MDCK cells grown in serum-free medium for influenza virus production. Dev Biol Stand 98:13-21
39. Klenk HD, Rott R, Orlich M, Blodorn J (1975) Activation of influenza A viruses by trypsin treatment. Virology 68:426-439
40. Kovar J, Franek C (1987) Iron compounds at high concentrations enable mouse hybridoma and myeloma cells to grow in protein-free medium. Eur Congr Biotechnol 3:614-617
41. Kunz C, Hofmann H, Bachmayer H, Liehl E, Moritz AJ (1977) Clinical trials with a new influenza subunit vaccine in adults and children. Dev Biol Stand 39:297-302 (Pubitemid 9093026)
42. Kürsteiner O, Moser C, Lazar H, Durrer P (2006) Inflexal V - the influenza vaccine with the lowest ovalbumin content. Vaccine 24:6632-6635 (Pubitemid 46107152)
43. Künzi V, Dornseiff M, Horwath J, Hartmann K (2009) Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 27:1261-1265
44. Kuwert EK, Höher PG, Werner J, Scheiermann N, Thraenhart O, Müller B, Kleber G (1977) Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines. Dev Biol Stand 39:77-83 (Pubitemid 9073229)
45. Latham T, Galarza JM (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75:6154-6165 (Pubitemid 32553146)
46. Litwin J (1992) The growth of Vero cells in suspension as cell-aggregates in serum-free media. Cytotechnology 10:169-174
47. Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U (2009) New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 27:4975-4982
48. Lowy RJ (2003) Influenza virus induction of apoptosis by intrinsic and extrinsic mechanisms. Int Rev Immunol 22:425-449
49. Luschow D, Werner O, Mettenleiter TC, Fuchs W (2001) Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene. Vaccine 19:4249-4259 (Pubitemid 32703647)
50. Lyles DS (2000) Cytopathogenesis and inhibition of host gene expression by RNA viruses. Microbiol Mol Biol Rev 64:709-724
51. Mendonça RZ, Arrózio SJ, Antoniazzi MM, Ferreira JMC, Pereira CA (2002) Metabolic active-high density Vero cell cultures on microcarriers following apoptosis prevention by galactose/glutamine feeding. J Biotechnol 97:13-22 (Pubitemid 34607504)
52. Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S (1996) Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 397:141-151 (Pubitemid 126441238)
53. Merten OW, Manuguerra JC, Hannoun C, van der Werf S (1999) Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 98:23-37
54. Möhler L, Flockerzi D, Sann H, Reichl U (2005) Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol Bioeng 90:46-58 (Pubitemid 40547038)
55. Morris SJ, Price GE, Barnett JM, Hiscox SA, Smith H, Sweet C (1999) Role of neuraminidase in influenza virus-induced apoptosis. J Gen Virol 80:137-146 (Pubitemid 29041692)
56. Nagata K, Kawaguchi A, Naito T (2008) Host factors for replication and transcription of the influenza virus genome. Rev Med Virol 18:247-260 (Pubitemid 352018848)
57. Nayak DP, Balogun RA, Yamada H, Zhou ZH, Barman S (2009) Influenza virus morphogenesis and budding. Virus Res 143:147-161
58. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163 (Pubitemid 29474420)
59. Neumann G, Kawaoka Y (1999) Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Adv Virus Res 53:265-300
60. Nishiyama K, Sugawara K, Nouchi T, Kawano N, Soejima K, Abe S, Mizokami H (2008) Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologicals 36:122-133 (Pubitemid 351282488)
61. Oh DY, Barr IG, Mosse JA, Laurie KL (2008) MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 46:2189-2194
62. Paillet C, Forno G, Kratje R, Etcheverrigaray M (2009) Suspension- Vero cell cultures as a platform for viral vaccine production. Vaccine 27:6464-6467
63. Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X, Kobasa D, Kobinger GP (2009) Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27:3083-3089
64. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19:2716-2721 (Pubitemid 32234294)
65. Quesney S, Marc A, Gerdil C, Gimenez C, Marvel J, Richard Y, Meignier B (2003) Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium. Cytotechnology 42:1-11 (Pubitemid 37372941)
66. Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A (2004) Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res 103:187-193 (Pubitemid 38649078)
67. Schild GC, Oxford JS, de Jong JC, Webster RG (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706-709 (Pubitemid 13106735)
68. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML (2000) Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278:55-59 (Pubitemid 32002594)
69. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U (2009) Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production - flow cytometry and mathematical modeling. Vaccine 27:2712-2722
70. Sidorenko Y, Reichl U (2004) Structured model of influenza virus replication in MDCK cells. Biotechnol Bioeng 88:1-14 (Pubitemid 39388688)
71. Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM (2008) High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 26:3778-3782
72. Stanley WM (1945) The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J Exp Med 81:193-218
73. Stech J, Garn H, Wegmann M, Wagner R, Klenk HD (2005) A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11:683-689 (Pubitemid 40868311)
74. Stray SJ, Air GM (2001) Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis. Virus Res 77:3-17 (Pubitemid 32622805)
75. Takada A, Kuboki N, Okazaki K, Ninomiya A, Tanaka H, Ozaki H, Itamura S, Nishimura H, Enami M, Tashiro M, Shortridge KF, Kida H (1999) Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 73:8303-8307 (Pubitemid 29441691)
76. Tharmalingam T, Ghebeh H, Wuerz T, Butler M (2008) Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol 39:167-177
77. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19:3444-3450 (Pubitemid 32710294)
78. Vaidya NK, Huang H, Takagi S (2007) Modelling HA protein-mediated interaction between an influenza virus and a healthy cell: pre-fusion membrane deformation. Math Med Biol 24:251-270 (Pubitemid 350120290)
79. Vester D, Rapp E, Gade D, Genzel Y, Reichl U (2009) Quantitative analysis of cellular proteome alterations in human influenza A virus-infected mammalian cell lines. Proteomics 9:3316-3327
80. Voeten JTM, Brands R, Palache AM, van Scharrenberg GJM, Rimmelzwaan GF, Osterhaus ADME, Claas ECJ (1999) Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine 17:1942-1950 (Pubitemid 29172364)
81. Wahl A, Sidorenko Y, Dauner M, Genzel Y, Reichl U (2008) Metabolic flux model for an anchorage-dependent MDCK cell line: characteristic growth phases and minimum substrate consumption flux distribution. Biotechnol Bioeng 101:135-152
82. Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn A (2010) In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy. Ann Allergy Asthma Immunol 104:426-433
83. Watabe S, Xin KQ, Ihata A, Liu LJ, Honsho A, Aoki I, Hamajima K, Wahren B, Okuda K (2001) Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434-4444 (Pubitemid 32718667)
84. Webster RG, Laver WG, Kilbourne ED (1968) Reactions of antibodies with surface antigens of influenza virus. J Gen Virol 3:315-326
85. Zavala G, Cheng S (2006) Experimental infection with avian leukosis virus isolated from Marek's disease vaccines. Avian Dis 50:232-237 (Pubitemid 44077085)
86. Zhirnov O, Klenk HD (2003) Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology 313:198-212 (Pubitemid 37013604)